KARYOPHARM THERAPEUTICS - TO SUBMIT SNDA TO FDA IN AUGUST 2026 FOR SELINEXOR PLUS RUXOLITINIB IN MYELOFIBROSIS

Reuters · 1d ago

Please log in to view news